MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Sialorrhea"

  • 2024 International Congress

    Oral health in Parkinson’s disease patients from countries with different economies: preliminary results of the OralPark study.

    S. Rota, L. Batzu, A. Biondi, I. Boura, D. Urso, S. Diaconu, Y. Lau, I. Inês, P. Tall, P. Lyra, S. Puspasari, S. Gilani, P. Zinzalias, L. Neumaier, P. Pablo, C. Santoro, S. Landolfo, K. Popławska-Domaszewicz, C. Spanaki, P. Odin, DK. Sreenivas, LK. Prashanth, C. Falup-Pecurariu, A. Rizos, J. Botelho, KR. Chaudhuri (UK, United Kingdom)

    Objective: To characterize oral health in Parkinson’s disease (PD) patients from countries with different economies. Background: Oral diseases are the most frequent conditions globally and…
  • 2024 International Congress

    Patient Characteristics and Real-World Use of Botulinum Toxins for Treatment of Chronic Sialorrhea

    M. Hast, A. Kong, J. Abdelhadi, A. Szendrey, R. Shah, J. Holmes (Raleigh, USA)

    Objective: We aimed to describe the demographics, clinical characteristics, and treatment patterns among patients with evidence of chronic sialorrhea. Background: Patients with neurological impairment may…
  • 2024 International Congress

    Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC)). Background:…
  • 2023 International Congress

    Is a Parkinson’s Sialorrhoea service effective?

    C. Williams, J. Adenwalla, B. Mohamed, C. Marquis, C. Thomas, R. Lewis-Morton (cardiff, United Kingdom)

    Objective: Evaluate the efficacy and tolerance of Botulinum Toxin A (BoNT A) in managing sialorrhoea in People with Parkinsons (PwP)Assess impact on quality of life…
  • 2023 International Congress

    Recommendations to tackle under-recognition and under-treatment of sialorrhea in Parkinson’s Disease: Is it time for a paradigm shift?

    B. Bergmans, V. Clark, S. Isaacson, T. Bäumer (Bruges, Belgium)

    Objective: To leverage patient survey data and expert opinion to develop recommendations for managing sialorrhea in patients with Parkinson’s disease (PD). Background: Sialorrhea, or drooling,…
  • 2023 International Congress

    Experiences of People with Parkinson’s Disease use of a wearable technology for the management of drooling; qualitative insights from the Cue Band study

    L. Dismore, K. Montague, T. Guerreiro, L. Carvalho, D. Jackson, R. Walker (Newcastle upon Tyne, United Kingdom)

    Objective: In the Cue Band study, people with Parkinson’s Disease (PwP) are participating in a randomised controlled trial to compare a mobile Application (App) with…
  • 2023 International Congress

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study: 4-year interim results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, L. Delameilleure, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea. Background: Sialorrhea is frequently a…
  • 2023 International Congress

    An Exploration of the Psychosocial Impact of Receiving Treatment at a Sialorrhea Clinic for People with Parkinson’s Disease

    M. Vazirian Zadeh, J. Adenwalla, C. Marquis, B. Mohamed, C. Thomas, R. Lewis-Morton (Penarth, United Kingdom)

    Objective: To explore the psychosocial impact (impact on quality of life, self-compassion, self-esteem & shame) of receiving treatment for sialorrhea in people with Parkinson’s. Background:…
  • 2022 International Congress

    IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions

    W. Jost, F. Pagan (Wolfach, Germany)

    Objective: To summarize clinical experience with incobotulinumtoxinA (INCO) for treating chronic sialorrhea due to Parkinson’s disease (PD), atypical parkinsonism, stroke, or traumatic brain injury in…
  • 2022 International Congress

    Evaluation of an Oral Health Questionnaire in Parkinson’s Disease to Facilitate a Multi-disciplinary Approach to improving Care Through Education

    J. Price, H. Martin, L. Ebenezer (Bronllys, Powys, United Kingdom)

    Objective: To determine if the oral health questionnaire (OHQ) devised could help to promote good oral hygiene in Parkinson’s disease (PD) while considering the potential…
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley